Een onderzoek naar JNJ-88549968 voor de behandeling van calreticuline (CALR)-gemuteerde myeloproliferatieve neoplasmata
Een eerste onderzoek bij mensen naar de veiligheid, farmacokinetiek en farmacodynamiek van JNJ-88549968, een T-cel-omleidend bispecifiek antilichaam voor CALR-gemuteerde myeloproliferatieve neoplasmata
The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D[s]) and optimal dosing schedule(s) of JNJ-88549968 in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s) in part 2 (Cohort Expansion). For U.S. sites: the purpose of this study is to characterize the safety and to determine the RP2D(s) and optimal dosing schedule(s) of JNJ-88549968 in Part 1 and part 1b (Dose Escalation), and to characterize the safety of JNJ-88549968 at the RP2D(s) in Part 2 and part 2b (Cohort Expansion), when given as monotherapy in essential thrombocythemia (ET) or myelofibrosis (MF), and with ruxolitinib or momelotinib in MF only.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Study Contact
- Telefoonnummer: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Studie Locaties
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N1
- Werving
- Arthur J E Child Comprehensive Cancer Centre
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1Z5
- Werving
- Princess Margaret Cancer Centre University Health Network
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Voltooid
- Jewish General Hospital
-
-
-
-
-
Beijing, China, 100032
- Werving
- Peking Union Medical College Hospital
-
Hangzhou, China, 310002
- Werving
- The First Affiliated Hospital Zhejiang University School of Medicine
-
Tianjin, China, 301617
- Werving
- Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
-
-
-
-
-
Aachen, Duitsland, 52074
- Werving
- Universitaetsklinikum der RWTH Aachen
-
Berlin, Duitsland, 12203
- Werving
- Charite Campus Benjamin Franklin
-
Essen, Duitsland, 45147
- Werving
- Med. Universitatsklinik Essen
-
Hanover, Duitsland, 30625
- Werving
- Medizinische Hochschule Hannover
-
Heidelberg, Duitsland, 69120
- Werving
- Universitaetsklinikum Heidelberg
-
Regensburg, Duitsland, 93053
- Werving
- Universitaetsklinikum Regensburg
-
-
-
-
-
Paris, Frankrijk, 75475
- Werving
- Hopital Saint Louis
-
Pierre-Bénite, Frankrijk, 69495
- Werving
- CH LYON SUD - Hematology
-
Toulouse, Frankrijk, 31059
- Werving
- Institut Universitaire du Cancer Toulouse Oncopole
-
-
-
-
-
Haifa, Israël, 3436212
- Werving
- Carmel Medical Center
-
Jerusalem, Israël, 9112001
- Werving
- Hadassah University Hospita Ein Kerem
-
Ramat Gan, Israël, 5266202
- Werving
- Sheba Medical Center
-
Tel Aviv, Israël, 64239
- Werving
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Bologna, Italië, 40138
- Werving
- Policlinico Sant'Orsola Malpighi
-
Milan, Italië, 21022
- Werving
- Policlinico di Milano
-
-
-
-
-
Bunkyō City, Japan, 113 8431
- Werving
- Juntendo University Hospital
-
Kashiwa, Japan, 277 8577
- Werving
- National Cancer Center Hospital East
-
-
-
-
-
Badalona, Spanje, 08916
- Werving
- Hosp. Univ. Germans Trias I Pujol
-
Valencia, Spanje, 46010
- Werving
- Hosp. Clinico Univ. de Valencia
-
-
-
-
-
London, Verenigd Koninkrijk, SE1 9RT
- Werving
- Guy's and St Thomas' Hospital
-
London, Verenigd Koninkrijk, NW1 2PG
- Werving
- University College London Hospitals Nhs Foundation Trust
-
Oxford, Verenigd Koninkrijk, OX3 7LE
- Werving
- Churchill Hospital
-
-
-
-
Arizona
-
Goodyear, Arizona, Verenigde Staten, 85338
- Werving
- City of Hope Phoenix
-
-
California
-
Duarte, California, Verenigde Staten, 91010
- Werving
- City of Hope
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- Werving
- UCHealth Cancer Care Anschutz Medical Campus University of Colorado Cancer Center
-
-
Florida
-
Tampa, Florida, Verenigde Staten, 33612
- Werving
- Moffit Cancer center
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Werving
- Emory University
-
-
Illinois
-
Zion, Illinois, Verenigde Staten, 60099
- Werving
- City of Hope Chicago
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109
- Werving
- University of Michigan
-
Grand Rapids, Michigan, Verenigde Staten, 49546
- Werving
- Start Midwest
-
-
New Jersey
-
East Brunswick, New Jersey, Verenigde Staten, 08816
- Werving
- START New Jersey
-
New Brunswick, New Jersey, Verenigde Staten, 08901
- Werving
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
New York, New York, Verenigde Staten, 10065
- Werving
- Memorial Sloan Kettering Cancer Center
-
The Bronx, New York, Verenigde Staten, 10467
- Werving
- Montefiore Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, Verenigde Staten, 28204
- Werving
- Levine Cancer Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Werving
- University of Pennsylvania
-
-
South Carolina
-
Greenville, South Carolina, Verenigde Staten, 29605
- Werving
- Prisma Health
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- Werving
- Sarah Cannon Cancer Institute
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- MD Anderson Cancer Center
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98104
- Werving
- Swedish Cancer Institute
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Be greater than or equal to (>=) 18 years of age (or the legal age of majority in the jurisdiction in which the study is taking place, whichever the greater) at the time of informed consent
- Positive for a calreticulin (CALR) driver mutation of essential thrombocythemia (ET) or myelofibrosis (MF)
- Participants with ET and MF with risk characteristics as described in the protocol
- Have an Eastern Cooperative Oncology Group (ECOG) performance status grade of less than or equal to (<=) 2
- For US sites: Eligible for ruxolitinib therapy as per drug label for participants naive to a janus kinase (JAK) inhibitor
Exclusion Criteria:
-
Known allergies, hypersensitivity, or intolerance to the excipients of the study treatment
-
Concurrent or recently diagnosed or treated malignancies present at the time of participant screening. Exceptions are squamous and basal cell carcinoma of the skin, carcinoma in situ of the cervix, and any malignancy that is considered cured or has minimal risk of recurrence within 1 year of first dose of study treatment in the opinion of both the investigator and sponsor's medical monitor. Participants cured of another malignant disease with no sign of relapse greater than or equal to (>=) 3 years after treatment ended are allowed to enter the study
-
Prior solid organ transplantation
-
Either of the following regarding hematopoietic stem cell transplantation:
- Prior treatment with allogenic stem cell transplant less than or equal to (<=) 6 months before the first dose of JNJ-88549968 or
- Evidence of graft versus host disease (GVHD) that requires immunosuppressant therapy
-
History of clinically significant cardiovascular disease within 6 months prior to the first dose of study treatment
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Dose Escalation (Part 1), Dose Expansion (Part 2) and Part 1b (US only), Part 2b (US only)
In dose escalation (Part 1), participants will receive JNJ-88549968. For myelofibrosis (MF) participants only, the study will explore a Phase 1b cohort in which the janus kinase (JAK) inhibitor ruxolitinib or momelotinib is started in combination with JNJ-88549968. The dose will be escalated sequentially to determine the recommended phase 2 dose (RP2D) and optimal dosing schedule (s) based on safety, pharmacokinetic, pharmacodynamic, and preliminary assessment of efficacy across several dose regimens. Additional Cohorts may be added to assess different formulation or delivery methods. In dose expansion (Part 2, Part 2b [US only]), participants will receive JNJ-88549968 at the RP2D regimen(s) determined in dose escalation (Part 1, Part 1b [US only]). |
JNJ-88549968 will be administered. For US sites: Ruxolitinib will be administered for participants with MF only. For US sites: Momelotinib will be administered for participants with MF only. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Part 1, Part 1b (US Only): Number of Participants With Dose Limiting Toxicity (DLT)
Tijdsspanne: Approximately up to 35 days after first dose of study treatment
|
Number of participants with DLT will be reported. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity. For US only: A DLT is any adverse event attributed to study treatment that meets the criteria for severity and duration and that occurs during the evaluation periods unless it can be incontrovertibly attributed to disease or other extraneous cause such as an accident. |
Approximately up to 35 days after first dose of study treatment
|
|
Part 1, 2, Part 1b (US Only), Part 2b (US Only): Number of Participants with Adverse Events (AEs)
Tijdsspanne: Up to 2 years
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
Up to 2 years
|
|
Part 1, 2, Part 1b (US Only), Part 2b (US Only): Number of Participants with Adverse Events (AEs) by Severity
Tijdsspanne: Up to 2 years
|
An adverse event is any untoward medical occurrence in a clinical study participant that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from grade 1 (mild) to grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse event. Cytokine release syndrome (CRS) and associated neurologic toxicity events (immune effector cell-associated neurotoxicity syndrome events [ICANS]) will be graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) guidelines. |
Up to 2 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Part 1, 2, Part 1b (US Only), Part 2b (US Only): Serum Concentration of JNJ-88549968
Tijdsspanne: Up to 2 years
|
Serum samples will be analyzed to determine concentrations of JNJ-88549968. |
Up to 2 years
|
|
Part 1, 2, Part 1b (US Only), Part 2b (US Only): Number of Participants With Presence of Anti-Drug Antibodies to JNJ-88549968
Tijdsspanne: Up to 2 years
|
Number of participants with presence of anti-drug antibodies to JNJ-88549968 will be reported. |
Up to 2 years
|
|
Part 1, 2, Part 1b (US Only), Part 2b (US Only): Overall Response Rate
Tijdsspanne: Up to 2 years
|
ORR is defined as the percentage of participants who achieve partial response (PR) and complete response (CR) according to modified International Working Group-Myeloproliferative Neoplasm Research and Treatment (IWG-MRT) criteria and modified European Leukemia Net (ELN) consensus report. |
Up to 2 years
|
|
Part 1, 2, Part 1b (US Only), Part 2b (US Only): Complete Response (CR) Rate
Tijdsspanne: Up to 2 years
|
CR rate is defined as the percentage of participants who achieve a best response of CR according to disease as defined in modified IWG-MRT criteria and modified ELN consensus report. |
Up to 2 years
|
|
Part 1, 2, Part 1b (US Only), Part 2b (US Only): Time to Response (TTR)
Tijdsspanne: Up to 2 years
|
TTR is defined for participants who achieved PR or CR as the time from the first dose of study treatment to first response of PR or CR according to modified IWG-MRT criteria and modified ELN consensus report. |
Up to 2 years
|
|
Part 1, 2, Part 1b (US Only), Part 2b (US Only): Duration of Response (DOR)
Tijdsspanne: Up to 2 years
|
DOR is defined for participants who achieved PR or CR as the time between the date of initial documentation of PR or CR to the date of first documented evidence of disease progression, as defined in modified IWG-MRT criteria and modified ELN consensus report, or death, whichever comes first. |
Up to 2 years
|
|
Part 2, Part 2b (US Only): Change From Baseline in Myeloproliferative Neoplasm (MPN) Symptom Burden
Tijdsspanne: Baseline up to 2 years
|
Change from baseline in MPN symptom burden assessed using patient reported outcome (PRO) questionnaire will be reported in this outcome measure. |
Baseline up to 2 years
|
Medewerkers en onderzoekers
Onderzoekers
- Studie directeur: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 88549968MPN1001
- 2023-505584-36-00 (Register-ID: EUCT number)
- 2023 (Subsidie/contract van de Amerikaanse NIH)
- 88549968MPN1001 (Andere identificatie: Janssen Research & Development, LLC)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .